SAVING  LIVES  

We at PharmaBio Labs fully appreciate the tremendous opportunity and challenge that is in front us – the opportunity to save lives and improve lives. 

Intravesical BCG

While BCG vaccines has for decades been the most widely used vaccine in the world covering 3 Billion people, there is still a remarkable 40% global demand shortfall for intravesical BCG, the primary therapy for bladder cancer, responsible for the deaths of 200,000 people in the world annually. 

The barriers to rapid production of intravesical BCG have been:

The lack of scientific know-how to produce high-yield bacterial strain and high-quality manufacturing process to produce the large quantities (800x concentration compared to BCG vaccine) needed

Ability to address regulatory requirements, be it GMP certified manufacturing or timely regulatory approvals. 

Insulin 

Similar to intravesical BCG, there are several other biologics that have barriers that result in unnecessary lives lost or lack of supply or low adherence due to cost. Another key area of our focus is insulin. 

With an estimated 500 million people affected by type 2 diabetes and double digit annual growth of this population in many parts of the developing world, insulin is a major focus for PharmaBio Labs. 

There are millions of lives adversely affected due to lack of insulin, the high cost of insulin when available and a lack of accessible drug delivery technology (such as insulin pens and patches). 

We have lined up and expanding on strategic partnerships to address this situation through a variety of methods including production of high-quality bulk insulin, production of low-cost, high-volume delivery technology and broader global reach through our distribution networ

BCG Potential for Covid-19 

BCG based vaccines and therapies have great potential to address COVID-19 and there are ongoing several clinical trials and efforts to confirming its efficacy. We continue to track the scientific community and stand by with ability to produce BCG based vaccines and therapies at large scale leveraging our high-yield technology.